Improving stroke risk prediction and individualised treatment in carotid atherosclerosis

Background: Unstable carotid atherosclerosis causes stroke, but methods to identify patients and lesions at risk are lacking. Currently, this risk estimation is based on measurements of stenosis and neurological symptoms, which determines the therapy of either medical treatment with or without carotid endarterectomy. The efficacy of this therapy is low and higher accuracy of diagnosis and therapy is warranted. Imaging of carotid plaque morphology using software for visualisation of plaque components may improve assessment of plaque phenotype and stroke risk. These studies aimed firstly to investigate if, and if yes, how, the carotid plaque morphology with image analysis of CTA associated with on-going biology in the corresponding specimen. Secondly, if risk stratification in clinical risk scores can be linked to the aforementioned associations. Finally, if the on-going biological processes can be specifically predicted out of the CTA imaging analysis. Methods: Plaque features were analysed in pre-operative CTA with dedicated software. In study I and II, the plaques were stratified according to quantified high and low of each feature, profiled with microarrays, followed by bioinformatic analyses. Immunohistochemistry was performed to evaluate the findings in plaques. In study III, patient phenotype, according to clinical stroke risk scores of CAR and ABCD2 stratified the cohorts of high vs low scores which were subsequently profiled with microarrays, followed by bioinformatic analyses and correlation analyses of plaque morphology in CTA. In study IV, the microarray transcriptomes were individually coupled to morphological data from the CTA analysis, developing models with machine intelligence to predict the gene expression from a CTA image. The models were then tested in unseen patients. Results: In study I, stabilising markers and processes related to SMCs and ECM organisation were associated with highly calcified plaques, while inflammatory and lipid related processes were repressed. PRG4, a novel marker for atherosclerosis, was identified as the most up-regulated gene in highly calcified plaques. Study II showed that carotid lesions with large lipid rich necrotic core, intraplaque haemorrhage or plaque burden were characterized by molecular signatures coupled with inflammation and extracellular matrix degradation, typically linked with instability. Symptomatology associated with large lipid rich necrotic core and plaque burden. Cross-validated prediction model for symptoms, showed that plaque morphology by CTA alone was superior to stenosis degree. Study III revealed that a high clinical risk score in CAR and ABCD2, reflect a plaque phenotype linked to immune response and coagulation, where the novel ABCB5, was one of the most up-regulated genes. The high risk scores correlated with the plaque components matrix and calcification but no positive association with stenosis degree. Study IV resulted in 414 robustly predicted transcripts from the CTA image analysis, of which pathway analysis showed biological processes associated with typical pathophysiology of atherosclerosis and plaque instability. The model testing demonstrated a good correlation between predicted and observed transcript expression levels and pathway analysis revealed a unique dominant mechanism for each individual. Conclusions: Biological processes in carotid plaques associated to vulnerability, can be linked to plaque morphology analysed with CTA image analysis. Patient phenotype classified with clinical risk scores associates to plaque phenotype and morphology in CTA. The biological processes in the atherosclerotic plaque can be predicted with plaque morphology CTA analysis in this small pilot study, providing a possibility to precision medicine after validation in larger scale studie

Contribution of endothelial injury and inflammation in early phase to vein graft failure: the causal factors impact on the development of intimal hyperplasia in murine models.

OBJECTIVES: Autologous veins are preferred conduits in by-pass surgery. However, long-term results are hampered by limited patency due to intimal hyperplasia. Although mechanisms involved in development of intimal hyperplasia have been established, the role of inflammatory processes is still unclear. Here, we studied leukocyte recruitment and intimal hyperplasia in inferior vena cava grafts transferred to abdominal aorta in mice. METHODS AND RESULTS: Several microscopic techniques were used to study endothelium denudation and regeneration and leukocyte recruitment on endothelium. Scanning electron microscopy demonstrated denudation of vein graft endothelium 7 days post-transfer and complete endothelial regeneration by 28 days. Examination of vein grafts transferred to mice transgenic for green fluorescent protein under Tie2 promoter in endothelial cells showed regeneration of graft endothelium from the adjacent aorta. Intravital microscopy revealed recruitment of leukocytes in vein grafts at 7 days in wild type mice, which had tapered off by 28 days. At 28 and 63 days there was significant development of intimal hyperplasia. In contrast; no injury, leukocyte recruitment nor intimal hyperplasia occurred in arterial grafts. Leukocyte recruitment was reduced in vein grafts in mice deficient in E- and P-selectin. In parallel, intimal hyperplasia was reduced in vein grafts in mice deficient in E- and P-selectin and in wild type mice receiving P-selectin/E-selectin function-blocking antibodies. CONCLUSION: The results show that early phase endothelial injury and inflammation are crucial processes in intimal hyperplasia in murine vein grafts. The data implicate endothelial selectins as targets for intervention of vein graft disease

IH in vascular grafts.

<p>Morphologic assessment of vascular grafts stained with Hematoxylin-eosin. (A) Upper panel demonstrates VGs in WT mice and in EP^−/− mice at different time point. Bar graphs represent IH area in AGs and VGs from WT and VGs from EP^−/− mice. (B) Lower panel demonstrates VGs in WT mice without or with treatment with combination of function-blockage antibodies against P- and E-selectin or rat IgG₁ λ isotype control in cuff-assisted vein grafting technique. Bar graph represents IH area. Error bars represent mean±SEM. *p<0.05. Scale bar = 100 µm. Arrows indicated IH of VGs.</p

Leukocyte rolling and adhesion in native vessels and vascular grafts.

<p>Intravital microscopic data on leukocyte recruitment. Bar graphs represent (A) leukocyte rolling and adhesion in native vessels in WT and EP^−/−mice, (B) leukocyte adhesion in AGs and VGs in WT and EP^−/− mice and (C) leukocyte rolling in AGs and VGs in WT mice at different time points. Bar graphs represent number of leukocytes that were visible in a 100×100 µm square during 30 seconds. Error bars represent mean±SEM. *p<0.05.</p

Endothelial structure in vascular grafts.

<p>Scanning electron microscopy images of endothelium in AGs and VGs (magnification 1K to 1.9K, scale bar = 50 µm). Images demonstrate endothelium in native aorta, native IVC (A), VGs and AGs (B) at different time point in WT mice. Bar graph shows endothelial coverage area change in AGs and VGs (C). Arrow = red blood cells, Triangle arrow = leukocytes, ** = denudated endothelium. Error bars represent mean±SEM. *p<0.05.</p

Endothelial regeneration in VGs.

<p>Confocal microscopy images of endothelium in IVC and in VGs. Endothelium of IVC in a Tie2-GFP mouse (A). Photomontage of confocal images of a FVB VG grafted into a Tie2-GFP recipient at 14 days (B) and at 28 days (C). The GFP-labeled endothelial cells located at center of a FVB VG at 28 days (C). Migration of GFP-labeled endothelial cells from aorta is evident by sequent time point. Zoomed images show photos in higher magnification. Isolated GFP-positive cells in center of grafts are also visible. Scale bar = 100 µm. Dotted line = Anastomosis between aorta and VG, Triangle head = isolated endothelial cells in middle of VG, Arrow = direction of blood flow.</p

Osteomodulin attenuates smooth muscle cell osteogenic transition in vascular calcification

RATIONALE: Vascular calcification is a prominent feature of late-stage diabetes, renal and cardiovascular disease (CVD), and has been linked to adverse events. Recent studies in patients reported that plasma levels of osteomodulin (OMD), a proteoglycan involved in bone mineralisation, associate with diabetes and CVD. We hypothesised that OMD could be implicated in these diseases via vascular calcification as a common underlying factor and aimed to investigate its role in this context. METHODS AND RESULTS: In patients with chronic kidney disease, plasma OMD levels correlated with markers of inflammation and bone turnover, with the protein present in calcified arterial media. Plasma OMD also associated with cardiac calcification and the protein was detected in calcified valve leaflets by immunohistochemistry. In patients with carotid atherosclerosis, circulating OMD was increased in association with plaque calcification as assessed by computed tomography. Transcriptomic and proteomic data showed that OMD was upregulated in atherosclerotic compared to control arteries, particularly in calcified plaques, where OMD expression correlated positively with markers of smooth muscle cells (SMCs), osteoblasts and glycoproteins. Immunostaining confirmed that OMD was abundantly present in calcified plaques, localised to extracellular matrix and regions rich in α-SMA+ cells. In vivo, OMD was enriched in SMCs around calcified nodules in aortic media of nephrectomised rats and in plaques from ApoE-/- mice on warfarin. In vitro experiments revealed that OMD mRNA was upregulated in SMCs stimulated with IFNγ, BMP2, TGFβ1, phosphate and β-glycerophosphate, and by administration of recombinant human OMD protein (rhOMD). Mechanistically, addition of rhOMD repressed the calcification process of SMCs treated with phosphate by maintaining their contractile phenotype along with enriched matrix organisation, thereby attenuating SMC osteoblastic transformation. Mechanistically, the role of OMD is exerted likely through its link with SMAD3 and TGFB1 signalling, and interplay with BMP2 in vascular tissues. CONCLUSION: We report a consistent association of both circulating and tissue OMD levels with cardiovascular calcification, highlighting the potential of OMD as a clinical biomarker. OMD was localised in medial and intimal α-SMA+ regions of calcified cardiovascular tissues, induced by pro-inflammatory and pro-osteogenic stimuli, while the presence of OMD in extracellular environment attenuated SMC calcification

Osteomodulin attenuates smooth muscle cell osteogenic transition in vascular calcification

RATIONALE: Vascular calcification is a prominent feature of late-stage diabetes, renal and cardiovascular disease (CVD), and has been linked to adverse events. Recent studies in patients reported that plasma levels of osteomodulin (OMD), a proteoglycan involved in bone mineralisation, associate with diabetes and CVD. We hypothesised that OMD could be implicated in these diseases via vascular calcification as a common underlying factor and aimed to investigate its role in this context.METHODS AND RESULTS: In patients with chronic kidney disease, plasma OMD levels correlated with markers of inflammation and bone turnover, with the protein present in calcified arterial media. Plasma OMD also associated with cardiac calcification and the protein was detected in calcified valve leaflets by immunohistochemistry. In patients with carotid atherosclerosis, circulating OMD was increased in association with plaque calcification as assessed by computed tomography. Transcriptomic and proteomic data showed that OMD was upregulated in atherosclerotic compared to control arteries, particularly in calcified plaques, where OMD expression correlated positively with markers of smooth muscle cells (SMCs), osteoblasts and glycoproteins. Immunostaining confirmed that OMD was abundantly present in calcified plaques, localised to extracellular matrix and regions rich in α-SMA+ cells. In vivo, OMD was enriched in SMCs around calcified nodules in aortic media of nephrectomised rats and in plaques from ApoE-/- mice on warfarin. In vitro experiments revealed that OMD mRNA was upregulated in SMCs stimulated with IFNγ, BMP2, TGFβ1, phosphate and β-glycerophosphate, and by administration of recombinant human OMD protein (rhOMD). Mechanistically, addition of rhOMD repressed the calcification process of SMCs treated with phosphate by maintaining their contractile phenotype along with enriched matrix organisation, thereby attenuating SMC osteoblastic transformation. Mechanistically, the role of OMD is exerted likely through its link with SMAD3 and TGFB1 signalling, and interplay with BMP2 in vascular tissues.CONCLUSION: We report a consistent association of both circulating and tissue OMD levels with cardiovascular calcification, highlighting the potential of OMD as a clinical biomarker. OMD was localised in medial and intimal α-SMA+ regions of calcified cardiovascular tissues, induced by pro-inflammatory and pro-osteogenic stimuli, while the presence of OMD in extracellular environment attenuated SMC calcification